Korsana Biosciences at UBS Global Biopharma Conference 2026: shuttle bet
On 16 November 2026, Korsana Biosciences (KRSA) highlighted its Alzheimer's lead therapy, KRSA-028, at the UBS Global Biopharma Conference 2026. KRSA-028 aims to improve upon existing Alzheimer's antibodies by incorporating pyroglutamate-selective targeting with a transferrin receptor shuttle. This shuttle enables better brain delivery and allows for once-monthly subcutaneous dosing via an auto-injector, as opposed to intravenous infusion.
KRSA-028 is designed to reduce safety concerns, such as anemia and amyloid-related imaging abnormalities (ARIA), compared to approved Alzheimer's treatments like lencemab and donanemab.
The company is currently investing over $450 million to develop KRSA-028, with the program expected to provide financial stability until 2029. CEO Jonathan Violin emphasized that KRSA-028 was engineered to surpass current anti-amyloid therapies in efficacy, safety, and convenience. The transferrin receptor shuttle strategy is considered one of the most reliable approaches in Alzheimer's research, as Roche has demonstrated promising results with trontinemab.
KRSA-028 integrates three key engineering modifications: pyroglutamate-selective amyloid-beta targeting, transferrin receptor shuttle, and Fc region engineering. These alterations target a plaque-enriched form of amyloid-beta, enhance microglial plaque clearance, and minimize complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity.
KRSA-028's design aims to achieve a once-monthly subcutaneous injection, reducing the need for intravenous administration and addressing safety issues associated with current therapies. The company's robust financial position, with a market capitalization of $1.53 billion and strong liquidity, supports its plans to execute KRSA-028 without immediate financing pressures.
The phase I/II study will involve healthy volunteers in Australia and New Zealand, with data expected in mid-2026. Subsequent trials in Alzheimer's patients will begin in early 2026, with interim safety data projected in late 2027 or Q1 2028. KRSA-028 is designed to match the average monthly exposure of Roche's trontinemab, while minimizing ARIA risks through its innovative shuttle approach.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.